Today's Hours: 8:00am - 6:00pm
Lane Medical Library

Search

Filter Results

Did You Mean:

Search Results

Sort by
relevance
  • Book
    Ximena Wortsman.
    Summary: This atlas presents a practical and systematic approach for performing dermatologic ultrasound. In recent years, the use of this imaging modality for diagnosing pathologic conditions of the skin, hair, nails, scalp, and soft tissues has grown dramatically and there is a demonstrated need for quick access to this information. For common dermatologic entities, richly-illustrated figures and drawings describe the ultrasound normal anatomy, technical guidelines, common findings, variants, key points, and tips and pitfalls. The extensive collection includes clinical and ultrasonographic correlations with 3D color Doppler ultrasound images and high-definition videos produced with state-of-the-art technology and relevant topics such as benign cutaneous and nail tumors and pseudotumors, skin cancer, vascular anomalies, facial ultrasound anatomy for cosmetic purposes, aesthetic complications, inflammatory diseases, etc. The Atlas of Dermatologic Ultrasound is a valuable resource and a must-have book for radiologists, dermatologists, plastic surgeons, sonographers, residents, and medical professionals who wish to strengthen their knowledge of the wide spectrum of sonographic presentations of dermatologic conditions and successfully integrate this field of ultrasound into their clinical practice.
    Digital Access Springer 2018
  • Article
    Smith CR, Maxwell RR, Edwards CQ, Rogers JF, Lietman PS.
    Johns Hopkins Med J. 1978 Mar;142(3):85-90.
    We evaluated 124 patients for nephrotoxicity associated with gentamicin or amikacin therapy. The incidence of definite nephrotoxicity was 10.5% during therapy, with a mean increase in creatinine of 1.0 mg/100 ml (range, 0.5-3.6 mg/100 ml). Nephrotoxicity developed late in therapy (mean, day 10) and the creatinine continued to increase after cessation of therapy for as long as nine days. Age, initial creatinine, total dose and initial "peak" and "valley" levels did not correlate with nephrotoxicity. Nephrotoxicity developed in 8 of 97 patients treated for less than or equal to 11 days and 5 of 19 treated for greater than 11 days (chi square, p less than .01). "Peak" and "valley" levels rose significantly (t-test, p less than .05) during therapy and increased more in those with nephrotoxicity. A "peak" level of amikacin of greater than or equal to 38.5 micrometer/ml or of gentamicin of greater than or equal to 10 micrometer/ml or a rise in the "valley" levels of amikacin above 10 micrometer/ml was also associated with nephrotoxicity (chi square, p less than .025). These data help define the natural history and the host and drug factors that affect the development of gentamicin- and amikacin-induced nephrotoxicity.
    Digital Access Access Options